These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 22815318)
1. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab. Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318 [TBL] [Abstract][Full Text] [Related]
2. Long-term efficiency of rituximab therapy in children with chronic immune thrombocytopenic purpura. Gurlek Gokcebay D; Guzelkucuk Z; Yarali N Transfus Apher Sci; 2018 Jun; 57(3):416-417. PubMed ID: 29753699 [No Abstract] [Full Text] [Related]
3. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Shanafelt TD; Madueme HL; Wolf RC; Tefferi A Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692 [TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905 [TBL] [Abstract][Full Text] [Related]
5. Rituximab for children with immune thrombocytopenia: a systematic review. Liang Y; Zhang L; Gao J; Hu D; Ai Y PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717 [TBL] [Abstract][Full Text] [Related]
7. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261 [TBL] [Abstract][Full Text] [Related]
8. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242 [TBL] [Abstract][Full Text] [Related]
9. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Rossignol J; Michallet AS; Oberic L; Picard M; Garon A; Willekens C; Dulery R; Leleu X; Cazin B; Ysebaert L Leukemia; 2011 Mar; 25(3):473-8. PubMed ID: 21127498 [TBL] [Abstract][Full Text] [Related]
10. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170 [TBL] [Abstract][Full Text] [Related]
11. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR; Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Pusiol A; Cesaro S; Nocerino A; Picco G; Zanesco L; Bisogno G Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911 [TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Miano M; Ramenghi U; Russo G; Rubert L; Barone A; Tucci F; Farruggia P; Petrone A; Mondino A; Lo Valvo L; Crescenzio N; Bellia F; Olivieri I; Palmisani E; Caviglia I; Dufour C; Fioredda F Br J Haematol; 2016 Nov; 175(3):490-495. PubMed ID: 27447678 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome. Torii Y; Yagasaki H; Tanaka H; Mizuno S; Nishio N; Muramatsu H; Hama A; Takahashi Y; Kojima S Int J Hematol; 2009 Sep; 90(2):174-176. PubMed ID: 19662467 [TBL] [Abstract][Full Text] [Related]
17. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Carey EJ; Somaratne K; Rakela J Rev Med Chil; 2011 Nov; 139(11):1484-7. PubMed ID: 22446656 [TBL] [Abstract][Full Text] [Related]
18. A patient with mixed type Evans syndrome: efficacy of rituximab treatment. Park CY; Chung CH J Korean Med Sci; 2006 Dec; 21(6):1115-6. PubMed ID: 17179698 [TBL] [Abstract][Full Text] [Related]
19. Maintenence rituximab following induction in autoimmune cytopenias. Rai MP; Lee EJ; Bussel JB Br J Haematol; 2023 Jul; 202(1):153-158. PubMed ID: 37086173 [TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic immune thrombocytopenic purpura with rituximab in children. Dogan M; Oner AF; Acikgoz M; Uner A Indian J Pediatr; 2009 Nov; 76(11):1141-4. PubMed ID: 20092026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]